|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, GREB1 loss may predict chemoresistance of endometrial cancer.
|
31744881 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, current tests typically use single type of biomarkers, and their sensitivity and specificity is often unsatisfactory.In this study, we developed a novel biomarker panel that measures both CEA level in blood and GREB1 and FRS2 levels in saliva to achieve high sensitivity and high specificity in detecting Non-Small Cell Lung Cancer (NSCLC).In the discovery phase, we achieved sensitivity of 96.67% and specificity of 93.33% for 30 NSCLC patients and 30 healthy controls.
|
31374012 |
2019 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Forced expression of β-catenin, YAP, and c-Met induces HB-like mouse liver tumor (BYM mice), with an increase in GREB1 expression and HB markers.
|
31462641 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We report a novel translocation t(2;3)(p25;p22) involving the GREB1 (intron 8) and CTNNB1 (exon 3) in a uterine tumor resembling ovarian sex cord tumor (UTROSCT), which exhibited extrauterine metastasis.
|
30350331 |
2019 |
|
Hepatoblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We propose that GREB1 is a target molecule of Wnt/β-catenin signaling and required for HB progression.
|
31462641 |
2019 |
|
Endometrial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also found that GREB1-deficient Ishikawa cells are much more resistant to chemotherapy and that human endometrial cancers with low GREB1 expression predict poor disease-free survival.
|
31744881 |
2019 |
|
Carcinogenesis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The CTNNB1 gene fusion, promoted by an estrogen-responsive gene (GREB1), could be a potential driver of tumorigenesis in this case and a therapeutic target with adapted inhibitors.
|
30350331 |
2019 |
|
Uterine tumor resembling ovarian sex cord tumor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report a novel translocation t(2;3)(p25;p22) involving the GREB1 (intron 8) and CTNNB1 (exon 3) in a uterine tumor resembling ovarian sex cord tumor (UTROSCT), which exhibited extrauterine metastasis.
|
30350331 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our study, we first demonstrated that eGREB1 derived from the enhancer of an oestrogen-responsive gene-GREB1 was up-regulated in BCa tissues, and the expression level of eGREB1 is positively associated with the histological grade and TNM stage of BCa.
|
30252203 |
2018 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our study, we first demonstrated that eGREB1 derived from the enhancer of an oestrogen-responsive gene-GREB1 was up-regulated in BCa tissues, and the expression level of eGREB1 is positively associated with the histological grade and TNM stage of BCa.
|
30252203 |
2018 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In a TMA of ovarian cancer cases, GREB1 was expressed in 75-85% of serous, endometrioid, mucinous, and clear cell carcinomas.
|
29973689 |
2018 |
|
Carcinoma of bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In our study, we first demonstrated that eGREB1 derived from the enhancer of an oestrogen-responsive gene-GREB1 was up-regulated in BCa tissues, and the expression level of eGREB1 is positively associated with the histological grade and TNM stage of BCa.
|
30252203 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we explored GREB1 function in ovarian cancer.
|
29973689 |
2018 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we explored GREB1 function in ovarian cancer.
|
29973689 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we explored GREB1 function in ovarian cancer.
|
29973689 |
2018 |
|
Developmental delay (disorder)
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
To investigate its function, we utilized TALEN-mediated knockout strategy and obtained a greb1 mutant zebrafish line. greb1 mutation caused convergent extension (CE) movement defect and developmental delay during gastrulation, and resulted in significant growth defects in zebrafish adults.
|
28606834 |
2017 |
|
Global developmental delay
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To investigate its function, we utilized TALEN-mediated knockout strategy and obtained a greb1 mutant zebrafish line. greb1 mutation caused convergent extension (CE) movement defect and developmental delay during gastrulation, and resulted in significant growth defects in zebrafish adults.
|
28606834 |
2017 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Although its exact function in the cascade of hormone action remains unclear, the ability of GREB1 to modulate tumor progression in models of breast, ovarian and prostate cancer renders this gene an excellent candidate for further consideration as a potential therapeutic target.
|
24998469 |
2014 |
|
Polycystic Ovary Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
RAD54B and GREB1 gene polymorphisms may not be associated with PCOS in the Han Chinese population.
|
23876972 |
2013 |
|
Aortic Valve Insufficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Associations between PCA3 and the androgen-receptor (AR) signaling pathway were investigated by treating LNCaP cells with 100 nM dihydrotestosterone (DHT) and with its antagonist (flutamide), and analyzing the expression of some AR-modulated genes (TMPRSS2, NDRG1, GREB1, PSA, AR, FGF8, CdK1, CdK2 and PMEPA1).
|
23130941 |
2012 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The logistic regression model combining five of the mRNA biomarkers (CCNI, EGFR, FGF19, FRS2, and GREB1) could differentiate lung cancer patients from normal control subjects, yielding AUC value of 0.925 with 93.75 % sensitivity and 82.81 % specificity in the pre-validation sample set.
|
22689099 |
2012 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The logistic regression model combining five of the mRNA biomarkers (CCNI, EGFR, FGF19, FRS2, and GREB1) could differentiate lung cancer patients from normal control subjects, yielding AUC value of 0.925 with 93.75 % sensitivity and 82.81 % specificity in the pre-validation sample set.
|
22689099 |
2012 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The logistic regression model combining five of the mRNA biomarkers (CCNI, EGFR, FGF19, FRS2, and GREB1) could differentiate lung cancer patients from normal control subjects, yielding AUC value of 0.925 with 93.75 % sensitivity and 82.81 % specificity in the pre-validation sample set.
|
22689099 |
2012 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In breast carcinomas, expression of GREB1 and AREG was associated with serum estradiol in all cancers and in the subgroup of estrogen receptor positive cases.
|
21812955 |
2011 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A set of nine genes that included GPCR11, cadherin 11, annexin A1, vimentin, lactate dehydrogenase B (upregulated in MDA-MB-231) and GREB1, S100A8, amyloid beta precursor protein, claudin 3 and cadherin 1 (downregulated in MDA-MB-231) were sufficient to distinguish MDA-MB-231 from MCF7 cells.
|
16314837 |
2006 |